Recent Research Analysts’ Ratings Changes for Stryker (SYK)

A number of research firms have changed their ratings and price targets for Stryker (NYSE: SYK):

• 7/13/2026 – Stryker was given a new $371.00 price target by BTIG Research.
• 7/9/2026 – Stryker was given a new $370.00 price target by Argus.
• 7/8/2026 – Stryker is now covered by BMO Capital Markets. They set an “outperform” rating and a $369.00 price target on the stock.
• 7/8/2026 – Stryker was upgraded by BMO Capital Markets to “strong-buy”.
• 7/6/2026 – Stryker was given a new $350.00 price target by Evercore Inc.
• 6/5/2026 – Stryker had its price target lowered by Leerink Partners from $410.00 to $407.00. They now have an “outperform” rating on the stock.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Insider Activity at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 over the last quarter. 4.60% of the stock is owned by corporate insiders.

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.